Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308903800> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4308903800 endingPage "S30" @default.
- W4308903800 startingPage "S30" @default.
- W4308903800 abstract "<h3>Introduction</h3> Clinical trial data showed patients who switched to oral berotralstat monotherapy reported consistently low hereditary angioedema (HAE) attack rates. Here we present preliminary efficacy data of patients in the United States who initiated berotralstat treatment in the real-world clinical setting and were previously on another prophylactic therapy. <h3>Methods</h3> Data was collected through the sole-source pharmacy and included patients with confirmed HAE Type I/II who actively received berotralstat 110 or 150mg from 12/16/2020-5/20/22 and were stratified by previous prophylaxis. Baseline attack rates were reported for the 90 days prior to berotralstat initiation. While on therapy, median attacks/month(25<sup>th</sup>,75<sup>th</sup> percentile) were calculated over each 90-day period by averaging each patient's monthly reported attack rate (1 month=∼28 days). Some patients did not report attack rates at each refill. <h3>Results</h3> In patients treated with prior prophylaxis(n=129) the median baseline attack rate was 1.7 attacks/month which decreased to 0.3(0,1.31) from days 1-90; 0.6(0,1.00) from days 91-180; 0.5(0.25,1.00) from days 181-270; and 0.5(0,1.50) from days 271-360. Specifically, in the lanadelumab group(n=53), the baseline attack rate of 1.0 attack/month decreased to 0(0,0.50) from days 1-90; 0.3(0,0.75) from 91-180; 0.5(0,1.00) from 181-270; and 0.5(0,1.38) from 271-360. In the subcutaneous C1-inhibitor group(n=31), the baseline attack rate of 1.7 attacks/month decreased to 0.8(0,2.00) from days 1-90; 0.7(0,2.08) from 91-180; 1.0(0.54,1.50) from 181-270; and 1.0(0.29,2.17) from 271-360. Patients without prior prophylaxis(n=112) had similar attack rate reductions. The most common adverse events reported were consistent with clinical trials. <h3>Conclusions</h3> Patients previously treated with another prophylactic therapy reported consistently low HAE attack rates when treated with once daily berotralstat." @default.
- W4308903800 created "2022-11-19" @default.
- W4308903800 creator A5011668253 @default.
- W4308903800 creator A5048414853 @default.
- W4308903800 creator A5051707472 @default.
- W4308903800 creator A5055677736 @default.
- W4308903800 creator A5056106175 @default.
- W4308903800 creator A5062111647 @default.
- W4308903800 date "2022-11-01" @default.
- W4308903800 modified "2023-09-24" @default.
- W4308903800 title "CONSISTENTLY LOW HEREDITARY ANGIOEDEMA ATTACK RATES OBSERVED WITH BEROTRALSTAT REGARDLESS OF PREVIOUS PROPHYLAXIS: REAL-WORLD OUTCOMES" @default.
- W4308903800 doi "https://doi.org/10.1016/j.anai.2022.08.590" @default.
- W4308903800 hasPublicationYear "2022" @default.
- W4308903800 type Work @default.
- W4308903800 citedByCount "0" @default.
- W4308903800 crossrefType "journal-article" @default.
- W4308903800 hasAuthorship W4308903800A5011668253 @default.
- W4308903800 hasAuthorship W4308903800A5048414853 @default.
- W4308903800 hasAuthorship W4308903800A5051707472 @default.
- W4308903800 hasAuthorship W4308903800A5055677736 @default.
- W4308903800 hasAuthorship W4308903800A5056106175 @default.
- W4308903800 hasAuthorship W4308903800A5062111647 @default.
- W4308903800 hasConcept C105795698 @default.
- W4308903800 hasConcept C107130276 @default.
- W4308903800 hasConcept C122048520 @default.
- W4308903800 hasConcept C126322002 @default.
- W4308903800 hasConcept C141071460 @default.
- W4308903800 hasConcept C16005928 @default.
- W4308903800 hasConcept C187212893 @default.
- W4308903800 hasConcept C2777788586 @default.
- W4308903800 hasConcept C2777995640 @default.
- W4308903800 hasConcept C33923547 @default.
- W4308903800 hasConcept C37701844 @default.
- W4308903800 hasConcept C535046627 @default.
- W4308903800 hasConcept C71924100 @default.
- W4308903800 hasConceptScore W4308903800C105795698 @default.
- W4308903800 hasConceptScore W4308903800C107130276 @default.
- W4308903800 hasConceptScore W4308903800C122048520 @default.
- W4308903800 hasConceptScore W4308903800C126322002 @default.
- W4308903800 hasConceptScore W4308903800C141071460 @default.
- W4308903800 hasConceptScore W4308903800C16005928 @default.
- W4308903800 hasConceptScore W4308903800C187212893 @default.
- W4308903800 hasConceptScore W4308903800C2777788586 @default.
- W4308903800 hasConceptScore W4308903800C2777995640 @default.
- W4308903800 hasConceptScore W4308903800C33923547 @default.
- W4308903800 hasConceptScore W4308903800C37701844 @default.
- W4308903800 hasConceptScore W4308903800C535046627 @default.
- W4308903800 hasConceptScore W4308903800C71924100 @default.
- W4308903800 hasIssue "5" @default.
- W4308903800 hasLocation W43089038001 @default.
- W4308903800 hasOpenAccess W4308903800 @default.
- W4308903800 hasPrimaryLocation W43089038001 @default.
- W4308903800 hasRelatedWork W1994618499 @default.
- W4308903800 hasRelatedWork W2015647057 @default.
- W4308903800 hasRelatedWork W2073981790 @default.
- W4308903800 hasRelatedWork W2725025256 @default.
- W4308903800 hasRelatedWork W2782841460 @default.
- W4308903800 hasRelatedWork W2886851188 @default.
- W4308903800 hasRelatedWork W2913393208 @default.
- W4308903800 hasRelatedWork W3127902009 @default.
- W4308903800 hasRelatedWork W3185247302 @default.
- W4308903800 hasRelatedWork W3186705653 @default.
- W4308903800 hasVolume "129" @default.
- W4308903800 isParatext "false" @default.
- W4308903800 isRetracted "false" @default.
- W4308903800 workType "article" @default.